Relative Contributions of Radiation and Cisplatin-Based Chemotherapy to Sensorineural Hearing Loss in Head-and-Neck Cancer Patients

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

Jay S. Cooper, Thomas F. Pajak, Arlene A. Forastiere et al. · New England Journal of Medicine · 2004 · 3.3K citations

Medicine, Oncology, Radiation Oncology +6

Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)

Jacques Bernier, Jay S. Cooper, Thomas F. Pajak et al. · Head & Neck · 2005 · 1.8K citations

Medicine, Otolaryngology, Radiation Oncology +10

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003

Karen K. Fu, Thomas F. Pajak, Andy Trotti et al. · International Journal of Radiation Oncology*Biology*Physics · 2000 · 1.4K citations

Medicine, Oncology, Radiation Oncology +17

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

Jean-Claude Horiot, P. Bontemps, Walter Van den Bogaert et al. · Radiotherapy and Oncology · 1997 · 505 citations

Medicine, Oncology, Radiation Oncology +17

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Felix E. de Jongh, Ruben N. van Veen, S J Veltman et al. · British Journal of Cancer · 2003 · 267 citations · Full text

Medicine, Oncology, Pharmacology +17